Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 274.4 SEK -0.72% Market Closed
Market Cap: kr8.6B

EV/GP

14.1
Current
26%
Cheaper
vs 3-y average of 19.1

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
14.1
=
Enterprise Value
kr8.6B
/
Gross Profit
kr599.5m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
14.1
=
Enterprise Value
kr8.6B
/
Gross Profit
kr599.5m

Valuation Scenarios

Xvivo Perfusion AB is trading below its 3-year average

If EV/GP returns to its 3-Year Average (19.1), the stock would be worth kr370.92 (35% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-72%
Maximum Upside
+64%
Average Downside
8%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 14.1 kr274.4
0%
3-Year Average 19.1 kr370.92
+35%
5-Year Average 23.2 kr450.42
+64%
Industry Average 3.9 kr76.02
-72%
Country Average 5.6 kr109.14
-60%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
P/E Multiple
Earnings Growth PEG
SE
Xvivo Perfusion AB
STO:XVIVO
Average P/E: 68.4
343.5
131%
2.6
JP
Hoya Corp
TSE:7741
37.6
N/A N/A
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
CH
Alcon AG
SIX:ALC
36.3
32%
1.1
DK
Coloplast A/S
CSE:COLO B
22.8
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
31.1
34%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -16 N/A N/A
UK
ConvaTec Group PLC
LSE:CTEC
31.1
41%
0.8
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
23
9%
2.6
CN
Intco Medical Technology Co Ltd
SZSE:300677
21.9
12%
1.8
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.5 N/A N/A

Market Distribution

Higher than 83% of companies in Sweden
Percentile
83nd
Based on 1 210 companies
83nd percentile
14.1
Low
0.1 — 3.3
Typical Range
3.3 — 9.2
High
9.2 —
Distribution Statistics
Sweden
Min 0.1
30th Percentile 3.3
Median 5.6
70th Percentile 9.2
Max 18 023.5

Xvivo Perfusion AB
Glance View

Market Cap
8.6B SEK
Industry
Health Care

Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted. Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.

XVIVO Intrinsic Value
261.55 SEK
Overvaluation 5%
Intrinsic Value
Price kr274.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett